Gemcitabine increases the IFN-gamma production by activated T-cells and CD69+ cells in pancreatic cancer patients [23], and augments the cell-mediated immune response in small-cell lung cancer patients (phase I clinical trial) [24]. This evidence concerns the gene IFNG and small cell lung carcinoma.